Combatting DKA with Integrated Sensors
MiniMed and Abbott collaborate on new sensors to detect life-threatening DKA early
MiniMed (NASDAQ: MMED) has struck an expanded exclusive deal with Abbott to bring the world's first dual glucose-ketone sensors to its smart insulin pump systems, the company announced June 3, 2026, according to PR Newswire. The sensors will feed real-time ketone data directly into MiniMed's dosing algorithm — a first for automated insulin delivery. MiniMed shares surged nearly 14% on the news, per Investing.com.
The move targets diabetic ketoacidosis, or DKA — a dangerous condition where the body builds up toxic levels of ketones due to too little insulin. DKA causes hundreds of thousands of U.S. hospitalizations each year and is the leading cause of death in people under 58 with type 1 diabetes, according to Newswire.
Abbott's New Dual Sensor Just Cleared Europe
Abbott's Libre Duo and Libre Duo 10 Day — the world's first sensors to measure both glucose and ketones simultaneously — received CE Mark approval in Europe on May 27, 2026, just days before this announcement, according to BioWorld. MiniMed now holds exclusive rights to sell these sensors for use with its pumps. Abbott makes the hardware; MiniMed controls the sales.
The new dual sensor keeps the same tiny footprint as MiniMed's current
Sentiment
NeutralPublishers
4
Articles
3
Reach
4
